Biotech Catalyst Calendar 2026
A practical conference map for biotech traders, researchers, and catalyst hunters. These are the major 2026 meetings most likely to influence attention, abstract-driven speculation, partnering chatter, and sector-wide momentum.
Why biotech may “wake up” in waves
April to June
This is the strongest near-term cluster for oncology and broader biotech attention: AACR, ASCO, Jefferies, EHA, and BIO all arrive in a fairly tight sequence.
October to December
ESMO, SITC, and ASH often create another meaningful cycle of readouts, poster interest, hematology attention, and late-year speculation.
Not one event — a sequence
The sector rarely wakes up all at once. It usually strengthens as multiple meetings, abstracts, analyst notes, financings, and partnering headlines begin to reinforce one another.
2026 conference schedule
🤝 BIO-Europe Spring 2026
One of the first major spring partnering checkpoints. Good for licensing chatter, business-development signals, and early sentiment shifts.
🧬 AACR Annual Meeting 2026
A major early-year oncology catalyst. Smaller names can get attention from posters, translational science, and first looks at emerging mechanisms.
🎤 ASCO Annual Meeting 2026
ASCO is one of the biggest oncology attention clusters of the year. Headlines, abstracts, investor notes, and sentiment can all compound around this meeting.
🏦 Jefferies Global Healthcare Conference
Important for management commentary, company slides, Q&A snippets, and investor framing across biotech, medtech, pharma, and life-science tools.
🦴 EULAR 2026 Congress
A major rheumatology and inflammatory-disease meeting. Useful for autoimmune, arthritis, lupus, inflammatory pathway, JAK/TYK/IL programs, and companies trying to position immune-modulating assets.
🩸 EHA2026 Congress
A key meeting for hematology names. Useful for leukemia, lymphoma, myeloma, MDS, MPN, and other blood-disorder developments.
🌎 ENDO 2026 — Endocrine Society Annual Meeting
Endocrinology research and clinical care; diabetes, obesity/metabolism, thyroid, endocrine cancers, reproductive hormones, pituitary/adrenal disorders, hormone science. The Endocrine Society describes it as a major global endocrinology meeting with 7,000+ attendees, nearly 2,500 abstracts, and 200+ sessions.
🌎 BIO International Convention 2026
This is broad biotech rather than a pure clinical-data conference. Still, it can influence sentiment through deal announcements, partnering expectations, and ecosystem visibility.
🫁 IASLC Hot Topic Conference: Resistance to Immunotherapy
A smaller but useful oncology checkpoint for companies tied to checkpoint resistance, tumor microenvironment strategies, biomarker-driven development, and next-generation cancer combinations.
🧠 EAN 2026 — European Academy of Neurology Congress
A useful late-June neurology catalyst window for Alzheimer’s, Parkinson’s, epilepsy, ALS, MS, migraine, neuromuscular, and CNS rare-disease names.
🧠 AAIC 2026 — Alzheimer’s Association International Conference
One of the most important summer attention clusters for dementia and neurodegeneration. Useful for Alzheimer’s antibodies, tau, amyloid, neuroinflammation, diagnostics, and biomarker-driven CNS stories.
🏦 Stifel Biotech Summer Summit
A useful summer investor checkpoint for management tone, post-ASCO thesis digestion, pipeline updates, and institutional positioning before the fall catalyst season.
🏦 Canaccord Genuity 46th Annual Growth Conference
A broad growth-company conference that can still matter for biotech visibility, management meetings, capital-market sentiment, and post-June thesis refreshes.
🌏 Evercore ISI China Biotech Summit
Useful for China-originated assets, licensing themes, pharma deal flow, and companies with China or Asia development exposure.
🫁 ERS Congress 2026 — European Respiratory Society
A major respiratory and pulmonary medicine meeting. Useful for asthma, COPD, interstitial lung disease, pulmonary hypertension, inhaled therapies, and fibrosis-related biotech programs.
🫁 WCLC 2026 — IASLC World Conference on Lung Cancer
A major oncology catalyst cluster for lung-cancer names, biomarker therapies, ADCs, immunotherapy combinations, EGFR/ALK/KRAS/MET/HER2 programs, and companion diagnostics.
☢️ Oppenheimer Radiopharmaceuticals Conference
A focused event for radioligand therapy names, isotope supply-chain stories, targeted oncology platforms, and acquisition or partnering speculation in radiopharma.
🏦 BofA Healthcare Trailblazers Private Company Conference
Mostly useful for ecosystem scouting: future public names, private-company competition, partnering themes, and where institutional capital is flowing before public-market visibility.
🏦 Bank of America Securities Global Healthcare Conference
A broad global healthcare investor conference that can influence institutional sentiment, management framing, and post-summer positioning across biotech, pharma, medtech, and life-science tools.
🏦 Sidoti September Small-Cap Conference
A useful visibility window for smaller biotech and healthcare companies seeking investor attention, financing support, and story re-introduction after the summer lull.
🧠 MDS 2026 — International Congress of Parkinson’s Disease and Movement Disorders
A focused CNS catalyst window for Parkinson’s, dystonia, tremor, Huntington’s, gene therapy, neuromodulation, and movement-disorder programs.
🦠 IDWeek 2026
A major infectious-disease meeting useful for anti-infective biotechs, vaccine platforms, resistance stories, hospital infectious-disease companies, and diagnostics.
🧫 ESMO Congress 2026
One of the major fall oncology catalysts. Often important for later-stage cancer programs and large attention spikes heading into year-end.
🛡️ SITC 2026
A focused immunotherapy conference that can matter a great deal for names tied to T-cell, IO combinations, and tumor-immunity narratives.
🧪 ASH Annual Meeting 2026
ASH is one of the most powerful late-year catalyst windows for blood-cancer and hematology names. It often helps define how biotech finishes the year.
How ScanScor can use this calendar
- Watch abstract release dates and company presentation schedules.
- Track financing risk ahead of binary readouts.
- Look for conference, webcast, fireside chat, and poster headlines.
- Compare primary-source company releases against media rewrites.
- Favor original data-heavy stories over wrapper pages and echoes.
- Use NDAPR on usable, material updates — not on every noisy repost.
- Study which names held gains versus faded.
- Track follow-on offerings, analyst notes, and FDA-path commentary.
- Measure whether the conference created a true thesis upgrade.